drugset / Trial / NCT06647732
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Phase 2
Recruiting
42 enrolled
Sun Yat-sen University
Beijing Tongren Hospital · collabFifth Affiliated Hospital of Guangzhou Medical University · collabFifth Affiliated Hospital, Sun Yat-Sen University · collabGansu Cancer Hospital · collabHuazhong University of Science and Technology · collabShenzhen People's Hospital · collabUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Zanubrutinib in combination with Rituximab as a first-line treatment for patients with mucosa-associated lymphoid tissue (MALT) extranodal marginal zone lymphoma.
Timeline
- Start
- 2024-10-30
- Primary completion
- 2028-08-31
- Completion
- 2028-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Zanubrutinib | Small molecule | 160 mg | — |